Seems reasonable to me. They have isolated the drugs so that each has distinct assets and IP and associated liabilities, which can be matched with the current and prospective revenues from each drug. In this way the drugs can be sold (or partnered) separately. This makes a lot of sense as the drugs are not complimentary to each other (they address very different needs) and probably more valuable piece by piece to 3 different buyers than together as a package to a buyer who really just wants 1 and considers the other 2 to be baggage.
If I could afford to buy all of them, I would not need to buy any of them and I sure wouldn't be spending time on the message boards!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.